Back HIV/AIDS HIV/AIDS Topics HIV Treatment

CROI 2015: Does Emtricitabine Work Better than Lamivudine in Combination ART?

People with HIV who started an antiretroviral regimen containing emtricitabine (FTC; Emtriva) and NNRTIs were about half as likely to experience virological treatment failure as those who used the similar drug lamivudine (3TC; Epivir), according to an analysis of more than 6000 participants in the Dutch ATHENA cohort presented at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. No significant differences between emtricitabine and lamivudine were seen with boosted protease inhibitor regimens.

alt

Read more:

CROI 2015: Researchers Discuss HIV Cure Strategies

Researchers at the recent 2015 Conference on Retroviruses and Opportunistic Infections in Seattle discussed a variety of approaches to achieve a functional cure, or prolonged remission of HIV. Most experts expect that a combination of multiple approaches will be needed.

Early Antiretroviral Treatment Reduces, but Does Not Eliminate HIV Reservoir

Experimental Agents Reverse HIV Latency, Help Immune System Fight Infected Cells

We May Need to Combine Many Approaches to Achieve a Cure for HIV

3/20/15

alt

 

CROI 2015: We May Need to Combine Many Approaches to Achieve a Cure for HIV

It is unlikely that one single approach will achieve a cure for HIV infection, according to research presenting at a community cure workshop held the day before the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

alt

Read more:

CROI 2015: Early Antiretroviral Treatment Reduces, but Does Not Eliminate HIV Reservoir

Starting antiretroviral therapy (ART) very soon after infection may limit the size of the HIV reservoir and delay viral rebound after treatment interruption, according to several presentations at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. Other research showed that various biomarkers may predict who will experience HIV rebound after stopping ART.

alt

Read more:

CROI 2015: Financial Incentives Did Not Improve Linkage to Care or HIV Viral Suppression

A U.S. study that offered patients gift cards to present for HIV care after testing, and also to stay in care and maintain an undetectable viral load, did not succeed in its main aims and with most patients. Rates of linkage to care, retention in care, and viral suppression were not significantly higher in centers where patients received gift cards than in ones where they did not, according to research presented at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. However, the study did produce some improvement in the proportion of people who remained in care. And it improved viral suppression rates in smaller and under-performing centers.

alt

Read more:

CROI 2015: Cabotegravir and Rilpivirine Effective for HIV Maintenance Therapy at 96 Weeks

A combination of 2 once-daily oral antiretrovirals -- the next-generation integrase inhibitor cabotegravir (GSK1265744) and the approved NNRTI rilpivirine -- was as effective as an efavirenz-based regimen when used as maintenance therapy to keep viral load suppressed, according to a poster presented at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

alt

Read more:

CROI 2015: Antiretroviral Therapy -- Past, Present and Future [VIDEO]

Antiretroviral therapy (ART) has undergone a remarkable evolution from AZT monotherapy in the late 1980s, to effective combination therapy in the mid-1990s, to today's well-tolerated single-tablet regimens. But questions about the optimal time to start treatment remain unanswered and getting ART to everyone who needs it is still a challenge, according to a presentation by David Cooper at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

alt

Read more: